In:
Blood Advances, American Society of Hematology, Vol. 2, No. 8 ( 2018-04-24), p. 923-932
Abstract:
In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts 〈 5%) was associated with improved response and OS.
Type of Medium:
Online Resource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2018016121
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2018
detail.hit.zdb_id:
2876449-3